^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Epithelial Ovarian Cancer

    Associations

    News

    Trials
    2d
    Cancer Antigen-125 and Carcinoembryonic Antigen in Determining Malignancy Risk in Epithelial Ovarian Tumor: An Observational Study. (PubMed, JNMA J Nepal Med Assoc)
    Cancer Antigen-125 showed high sensitivity and specificity in distinguishing malignant from benign epithelial ovarian tumors. Carcinoembryonic Antigen, while less sensitive, provided high specificity.
    Observational data • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    2d
    NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Nov 2026
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    3d
    Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study (clinicaltrials.gov)
    P=N/A, N=1300, Recruiting, Catholic University of the Sacred Heart | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Sep 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    3d
    Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. (PubMed, Signal Transduct Target Ther)
    Pharmacological modulation of lipid-driven signaling pathways through CCR5 inhibition (inflammation modulation through maraviroc) or blockade of the lipid scavenger receptor CD36 reprograms TAMs, restores T cell activity, and enhances antitumor immune responses within lipid-rich tumor niches...Consistent with these mechanistic insights, we demonstrated that the specific immunometabolic niche in omental metastases is clinically associated with responsiveness to ICB. We propose a non-invasive radiomics and machine-learning-based analysis of imaging data to assess omental involvement for patient stratification.
    Journal • IO biomarker
    |
    CD36 (thrombospondin receptor)
    |
    Selzentry (maraviroc)
    7d
    HERO: Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Nordic Society of Gynaecological Oncology - Clinical Trials Unit | N=350 --> 1000 | Trial completion date: Dec 2028 --> Jul 2032 | Trial primary completion date: Dec 2028 --> May 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    8d
    Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis. (PubMed, J Clin Med)
    No cases of myelodysplastic syndrome or acute myeloid leukemia were observed. In this large multicenter real-world cohort, first-line maintenance therapy with olaparib and niraparib provided durable PFS benefit in patients with advanced EOC, particularly among those with pathogenic BRCA mutations, confirming their effectiveness and manageable safety profiles in routine clinical practice.
    Retrospective data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • Zejula (niraparib)
    9d
    Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings. (PubMed, Expert Opin Investig Drugs)
    IMNN-001 gene therapy could add clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. IMNN-001 holds promise for synergistic combinations with immunotherapies requiring intrinsic immune activity.
    Review • Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    IMNN-001
    9d
    [Retracted] MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2. (PubMed, Oncol Lett)
    [This retracts the article DOI: 10.3892/ol.2016.5204.].
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    9d
    [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications (clinicaltrials.gov)
    P1/2, N=71, Recruiting, Blue Earth Diagnostics
    New P1/2 trial
    15d
    Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high-grade serous ovarian cancer. (PubMed, Mol Oncol)
    Further, KRT19 could contribute to paclitaxel resistance. Altogether, KRT19 represents a potential independent prognostic marker and therapeutic target to inhibit metastatic dissemination.
    Journal
    |
    KRT19 (Keratin 19)
    |
    paclitaxel
    16d
    Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Jan 2028 --> Jun 2026 | Trial primary completion date: Jan 2028 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA1 mutation • HRD
    |
    Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
    17d
    FAB: Functional Analysis of BRCAness (clinicaltrials.gov)
    P2, N=27, Terminated, Leiden University Medical Center | N=55 --> 27 | Recruiting --> Terminated; recruitment was lower than expected (28/55) due to registration of the IMP in the first and second line treatment
    Enrollment change • Trial termination
    |
    BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)
    |
    Lynparza (olaparib)